LPGO — Lipigon Pharmaceuticals AB Share Price
Last trade - 00:00- SEK36.16m
- SEK4.23m
- SEK32.81m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.27 | ||
| Price to Tang. Book | 1.27 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.1 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -86.98% | ||
| Return on Equity | -150.12% | ||
| Operating Margin | -75.4% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 3.48 | 8.02 | 4.42 | n/a | 32.81 | 12.5 | 18.5 | 444.44% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lipigon Pharmaceuticals AB is a Sweden-based project portfolio company. Lipigon's business concept is to develop medicines with new, unique mechanisms of action (so-called first-in-class) for diseases that lack adequate treatment. The Company develops medicines with a focus on diseases where the body's ability to handle fats is disturbed, so-called lipid-related diseases, and where there are unmet medical needs. Initially, the Company's development focuses on advanced diseases or genetically defined patient segments where it is possible to identify treatment effects early in the clinical development. It creates the conditions for studies with fewer patients and a shorter path to market approval and thus a reduced development risk.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 7th, 2010
- Public Since
- March 1st, 2021
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 126,422,281
- Address
- Tvistevagen 48 C, UMEA, 907 36
- Web
- https://www.lipigon.se/
- Phone
- Auditors
- KPMG AB
Upcoming Events for LPGO
Similar to LPGO
Biogaia AB
OMX Nordic Exchange Stockholm
BoneSupport Holding AB
OMX Nordic Exchange Stockholm
Calliditas Therapeutics AB
OMX Nordic Exchange Stockholm
Camurus AB
OMX Nordic Exchange Stockholm
Cline Scientific AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 21:48 UTC, shares in Lipigon Pharmaceuticals AB are trading at SEK0.29. This share price information is delayed by 15 minutes.
Shares in Lipigon Pharmaceuticals AB last closed at SEK0.29 and the price had moved by -20.33% over the past 365 days. In terms of relative price strength the Lipigon Pharmaceuticals AB share price has underperformed the FTSE Global All Cap Index by -29.3% over the past year.
There is no consensus recommendation for this security.
Lipigon Pharmaceuticals AB does not currently pay a dividend.
Lipigon Pharmaceuticals AB does not currently pay a dividend.
Lipigon Pharmaceuticals AB does not currently pay a dividend.
To buy shares in Lipigon Pharmaceuticals AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK0.29, shares in Lipigon Pharmaceuticals AB had a market capitalisation of SEK36.16m.
Here are the trading details for Lipigon Pharmaceuticals AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: LPGO
Based on an overall assessment of its quality, value and momentum Lipigon Pharmaceuticals AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Lipigon Pharmaceuticals AB is SEK1.75. That is 511.89% above the last closing price of SEK0.29.
Analysts covering Lipigon Pharmaceuticals AB currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lipigon Pharmaceuticals AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -33.1%.
As of the last closing price of SEK0.29, shares in Lipigon Pharmaceuticals AB were trading -36.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lipigon Pharmaceuticals AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK0.29.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Lipigon Pharmaceuticals AB's directors